<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568762</url>
  </required_header>
  <id_info>
    <org_study_id>CQBX258X2101</org_study_id>
    <nct_id>NCT01568762</nct_id>
  </id_info>
  <brief_title>To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled Study to Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 (Sequential Administration of a Fixed Dose of VAK694 and Single Ascending Doses of QAX576) in Patients With Well-controlled Mild to Moderate Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to compare the safety, tolerability, and pharmacokinetics of QBX258
      (sequential administration of a fixed dose of VAK694 and single ascending doses of QAX576) in
      patients with well-controlled mild to moderate asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>100 days</time_frame>
    <description>Adverse events will be determined by evaluating clinical, laboratory evaluations, impact on vital signs and impacts on ECGs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum anti-VAK694 antibodies</measure>
    <time_frame>Pre-dose, Day 71, 85 and 100</time_frame>
    <description>Blood will be collected to determine concentrations if anti-VAK964 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum anti-QAX576 antibodies</measure>
    <time_frame>Pre-dose, Day 71, 85 and 100</time_frame>
    <description>Blood will be collected to determine concentrations if anti-QAX576 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration curve for VAK694</measure>
    <time_frame>Pre-dose, 1, 2, 4, 11, 24, 48, 96 hours and Days 8, 15, 29, 43, 57, 71, 85, 100</time_frame>
    <description>Blood will be collected for the measurement of VAK694 serum concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration curve for QAX576</measure>
    <time_frame>Pre-dose, 1, 2, 4, 11, 24, 48, 96 hours and Days 8, 15, 29, 43, 57, 71, 85, 100</time_frame>
    <description>Blood will be collected for the measurement of QAX576 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin concentrations</measure>
    <time_frame>Pre-dose, 1, 2, 4, 11, 24, 48, 96 hours and Days 8, 15, 29, 43, 57, 71, 85, 100</time_frame>
    <description>Blood samples will be collected to measure interleukin concetrations.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>VAK694</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAK694 was administered as a 1 hour intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAK694 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>VAK694 placebo was administered as a one hour intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QAX576</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QAX576 was administered intravenously as a 2 hour infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QAX576 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>QAX576 placebo was administered as a 2 hour intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAK694</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>VAK694</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAK694 placebo</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>VAK694 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAX576</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>QAX576</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAX576 placebo</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>QAX576 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects age 18-60 years (inclusive)

          -  Well controlled mild to moderate atopic asthma

          -  Female subjects must be post-menopausal or surgically sterile

          -  Male subjects must be using two methods of contraception

          -  Subjects must have a positive skin prick test to one or more common airborne allergen

        Exclusion Criteria:

          -  Participation in any clinical investigation or use of other investigational drugs at
             time of enrollment

          -  A history of clinically significant ECG abnormalities

          -  History of malignancy of any organ system

          -  Smokers (use of tobacco products in the previous 3 months)

          -  Use of prescription drugs other than those required for control and relief of asthma

          -  Use of oral steroids within 12 weeks prior to dosing

          -  FEVI &lt; 80% predicted at screening or baseline

          -  Use of albuterol more than twice a week for relief of asthma

          -  Patients suffering from active hay fever at baseline or likely to require treatment
             during the study

          -  History of chronic respiratory disease other than asthma or chronic allergic rhinitis

          -  Emergency room visit within 6 weeks of screening due to asthma

          -  Hospitalization for asthma in the last year

          -  History of intubation/assisted ventilation for asthma in the last 5 years

          -  Administration of live vaccines within the preceding month

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>March 30, 2012</last_update_submitted>
  <last_update_submitted_qc>March 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>VAK694</keyword>
  <keyword>QAX576</keyword>
  <keyword>QBX258</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

